Dupixent, an injectable drug proposed for the treatment of moderate to severe atopic dermatitis in adults, awaits FDA decision on March 29, 2017. Atopic dermatitis, also known as atopic eczema, is a skin disorder that involves scaly and itchy rashes. This chronic disorder is more common in infants, but can also develop in children and adults. Dupixent, developed by Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) is also being explored in multiple indications, including asthma and pediatric atopic dermatitis.According to analysts, Dupixent could reach peak annual sales of up to $3 billion if approved for atopic dermatitis and asthma.Last December, the FDA approved a topical treatment for atopic dermatitis by the name Eucrisa, developed by Anacor Pharmaceuticals, which Pfizer Inc. (PFE) acquired last May. But Eucrisa targets a milder form of atopic dermatitis and it addresses a different patient population – i.e., patients two years of age and older.